As nanomaterials gain commercial traction, they have the potential to revolutionize medicine, aerospace, and 3D printing, and ...
When looking only at the past 12 months, Editas Medicine (NASDAQ: EDIT), a small-cap biotech company, seems to be doing well.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果